Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells

References

• Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger K. Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging 2004; 31 Suppl 1:S125-34; PMID:15085295.
   PubMedGoogle Scholar
• Li J, Xu LZ, He KL, Guo WJ, Zheng YH, Xia P, Chen Y. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. Breast Cancer Res 2001; 3:253-63; PMID:11434876.; http://dx.doi.org/10.1186/bcr303.
   PubMed Web of Science ®Google Scholar
• Baird RD, Kaye SB. Drug resistance reversal - are we getting closer? European J Cancer 2003; 39:2450-61; http://dx.doi.org/10.1016/S0959-8049(03)00619-1.
   PubMed Web of Science ®Google Scholar
• Jeansonne DP, Koh GY, Zhang F, Kirk-Ballard H, Wolff L, Liu D, Eilertsen K, Liu Z. Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells. Oncol Rep 2011; 25:1473-80; PMID:21331447.
   PubMed Web of Science ®Google Scholar
• Sui M, Jiang D, Hinsch C, Fan W. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor α to vinblastine and vinorelbine. Breast Cancer Res Treat 2010; 121:335-45; PMID:19626437.; http://dx.doi.org/10.1007/s10549-009-0472-4.
   PubMedGoogle Scholar
• Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor α mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res 2007; 67:5337-44; PMID:17545614.; http://dx.doi.org/10.1158/0008-5472.CAN-06-4582.
   PubMedGoogle Scholar
• Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001; 2:51-64; PMID:11258197.; http://dx.doi.org/10.1517/14622416.2.1.51.
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Tsukahara S, Imai Y, Ueda K, Tsuruo T. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther 2003; 2:105-12; PMID:12533678.
   PubMed Web of Science ®Google Scholar
• Liu ZH, Ma YL, He YP, Zhang P, Zhou YK, Qin H. Tamoxifen reverses the multi-drug-resistance of an established human cholangiocarcinoma cell line in combined chemotherapeutics. Mol Biol Rep 2011; 38:1769-75; PMID:20835928.; http://dx.doi.org/10.1007/s11033-010-0291-z.
   PubMed Web of Science ®Google Scholar
• Pickar JH, MacNeil T, Ohleth K. SERMs: progress and future perspectives. Maturitas 2010; 67:129-38; PMID:20580502.; http://dx.doi.org/10.1016/j.maturitas.2010.05.009.
   PubMed Web of Science ®Google Scholar
• Shanle EK, Xu W. Selectively targeting estrogen receptors for cancer treatment. Adv Drug Deliv Rev 2010; 62:1265-76; PMID:20708050.; http://dx.doi.org/10.1016/j.addr.2010.08.001.
   PubMed Web of Science ®Google Scholar
• Kiss Z, Crilly KS. Tamoxifen inhibits uptake and metabolism of ethanolamine and choline in multidrug-resistant, but not in drug-sensitive, MCF-7 human breast carcinoma cells. FEBS Lett 1995; 360:165-8; PMID:7875322.; http://dx.doi.org/10.1016/0014-5793(95)00094-P.
   PubMed Web of Science ®Google Scholar
• De Vincenzo R, Scambia G, Benedetti Panici P, Fattorossi A, Bonanno G, Ferlini C, Isola G, Pernisco S, Mancuso S. Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells. Int J Cancer 1996; 68:340-8; PMID:8903476.; http://dx.doi.org/10.1002/(SICI)1097-0215(19961104)68:3%3c340::AID-IJC12%3e3.0.CO;2-C.
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Jr, Wade JL 3rd, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295:2727-41; PMID:16754727.; http://dx.doi.org/10.1001/jama.295.23.joc60074.
   PubMed Web of Science ®Google Scholar
• Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord 2007; 8:229-39; PMID:17440819.; http://dx.doi.org/10.1007/s11154-007-9034-4.
   PubMed Web of Science ®Google Scholar
• Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007; 99:727-37; PMID:17470740.; http://dx.doi.org/10.1093/jnci/djk154.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361:296-300; PMID:12559863.; http://dx.doi.org/10.1016/S0140-6736(03)12342-2.
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652-62; PMID:16288118.; http://dx.doi.org/10.1093/jnci/dji372.
   PubMed Web of Science ®Google Scholar
• DeMichele A, Troxel AB, Berlin JA, Weber AL, Bunin GR, Turzo E, Schinnar R, Burgh D, Berlin M, Rubin SC, et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol 2008; 26:4151-9; PMID:18757329.; http://dx.doi.org/10.1200/JCO.2007.14.0921.
   PubMed Web of Science ®Google Scholar
• Jiang D, Sui M, Zhong W, Huang Y, Fan W. Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells. Cancer Lett 2013; 335:404-11; PMID:23499896.; http://dx.doi.org/10.1016/j.canlet.2013.02.059.
   PubMedGoogle Scholar
• Vogel VG. Recent results from clinical trials using SERMs to reduce the risk of breast cancer. Ann N Y Acad Sci 2006; 1089:127-42; PMID:17261762.; http://dx.doi.org/10.1196/annals.1386.010.
   PubMedGoogle Scholar
• Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371-88; PMID:9747868.; http://dx.doi.org/10.1093/jnci/90.18.1371.
   PubMed Web of Science ®Google Scholar
• Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 2001; 93:1449-57; PMID:11584060.; http://dx.doi.org/10.1093/jnci/93.19.1449.
   PubMed Web of Science ®Google Scholar
• Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 2009; 9:51-60; PMID:19105706.; http://dx.doi.org/10.1586/14737140.9.1.51.
   PubMed Web of Science ®Google Scholar
• Huang Y, Johnson KR, Norris JS, Fan W. Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 2000; 60:4426-32; PMID:10969788.
   PubMed Web of Science ®Google Scholar
• McDaid HM, Horwitz SB. Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol 2001; 60:290-301; PMID:11455016.
   PubMed Web of Science ®Google Scholar
• Sui M, Dziadyk JM, Zhu X, Fan W. Cell cycle-dependent antagonistic interactions between paclitaxel and gamma-radiation in combination therapy. Clin Cancer Res 2004; 10:4848-57; PMID:15269161.; http://dx.doi.org/10.1158/1078-0432.CCR-03-0707.
   PubMed Web of Science ®Google Scholar
• Wolf F, Wandke C, Isenberg N, Geley S. Dose-dependent effects of stable cyclin B1 on progression through mitosis in human cells. EMBO J 2006; 25:2802-13; PMID:16724106.; http://dx.doi.org/10.1038/sj.emboj.7601163.
   PubMedGoogle Scholar
• Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007; 7:495-507; PMID:17568790.; http://dx.doi.org/10.1038/nrc2169.
   PubMed Web of Science ®Google Scholar
• Cazales M, Boutros R, Brezak MC, Chaumeron S, Prevost G, Ducommun B. Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly. Mol Cancer Ther 2007; 6:318-25; PMID:17237290.; http://dx.doi.org/10.1158/1535-7163.MCT-06-0299.
   PubMed Web of Science ®Google Scholar
• Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G. Phosphorylation and activation of human cdc25-C by cdc2–cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J 1993; 12:53-63; PMID:8428594.
   PubMed Web of Science ®Google Scholar
• Dziadyk JM, Sui M, Zhu X, Fan W. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res 2004; 24:27-36; PMID:15015572.
   PubMed Web of Science ®Google Scholar
• Salah-Eldin AE, Inoue S, Tsukamoto S, Aoi H, Tsuda M. An association of Bcl−2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment. Int J Cancer 2003; 103:53-60; PMID:12455053.; http://dx.doi.org/10.1002/ijc.10782.
   PubMed Web of Science ®Google Scholar
• Haldar S, Jena N, Croce CM. Inactivation of Bcl−2 by phosphorylation. Proc Natl Acad Sci U S A 1995; 92:4507-11; PMID:7753834.; http://dx.doi.org/10.1073/pnas.92.10.4507.
   PubMed Web of Science ®Google Scholar
• Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, Longo DL. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 1998; 18:3509-17; PMID:9584191.; http://dx.doi.org/10.1128/MCB.18.6.3509.
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV, Giannakakou P, El-Deiry WS, Kingston DG, Higgs PI, Neckers L, Fojo T. Raf-1/bcl−2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 1997; 57:130-5; PMID:8988053.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ichijo H, Korsmeyer SJ. BCL−2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19:8469-78; PMID:10567572.
   PubMed Web of Science ®Google Scholar
• Liu ZH, He YP, Qin H. The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939. Mol Biol Rep 2010; 37:2693-701; PMID:19757172.; http://dx.doi.org/10.1007/s11033-009-9801-2.
   PubMedGoogle Scholar
• Zhang Y, Wang H, Wei L, Li G, Yu J, Gao Y, Gao P, Zhang X, Wei F, Yin D, et al. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. Breast Cancer Res Treat 2010; 123:679-89; PMID:19967559.; http://dx.doi.org/10.1007/s10549-009-0660-2.
   PubMedGoogle Scholar
• Li J, Xu LZ, Yao JJ, Guo WJ, Xia P, Chen Y. Reversal effects of droloxifene on multidrug resistance in adriamycin-resistant K562 cell line. Acta Pharmacol Sin 2001; 22:1023-7; PMID:11749795.
   PubMed Web of Science ®Google Scholar
• Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48:4827-33; PMID:3409223.
   PubMed Web of Science ®Google Scholar
• Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9; PMID:1710634.; http://dx.doi.org/10.1016/0022-1759(91)90198-O.
   PubMed Web of Science ®Google Scholar
• Duan Z, Choy E, Hornicek FJ. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One 2009; 4:e7415; PMID:19823672.; http://dx.doi.org/10.1371/journal.pone.0007415.
   PubMed Web of Science ®Google Scholar
• Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M, Debatin KM. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 2003; 63:3112-20; PMID:12810637.
   PubMed Web of Science ®Google Scholar